Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Matucci

Showing results (91-100 of 156) with videos related to

Pageof 16
Sort By:
Biofilm|March 22, 2024
Pathogenic avian mycoplasmas show phenotypic differences in their biofilm forming ability compared to non-pathogenic species <i>in vitro</i>Salvatore Catania, Marco Bottinelli, Alice Fincato, et al.
Clinical Drug Investigation|September 8, 2018
Direct and Indirect Costs of Immunoglobulin Replacement Therapy in Patients with Common Variable Immunodeficiency (CVID) and X-Linked Agammaglobulinemia (XLA) in ItalyRaffaella Viti, Andrea Marcellusi, Alessandro Capone, et al.
Biomedicines|February 27, 2026
Immunogenicity in Fabry Disease: Current Issues, Coping Strategies, and Future DirectionsAndrea Matucci, Sandro Feriozzi, Elena Biagini, et al.
International Archives of Allergy and Immunology|December 28, 2006
Detection by flow cytometry of ESAT-6- and PPD-specific circulating CD4+ T lymphocytes as a diagnostic tool for tuberculosisLorenzo Cosmi, Laura Maggi, Veronica Santarlasci, et al.
European Journal of Immunology|September 26, 2018
Omalizumab dampens type 2 inflammation in a group of long-term treated asthma patients and detaches IgE from FcεRILaura Maggi, Beatrice Rossettini, Gianni Montaini, et al.
Clinical Drug Investigation|February 13, 2015
Subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency in routine clinical practice: the VISPO prospective multicenter studyAlessandra Vultaggio, Chiara Azzari, Cinzia Milito, et al.
Immunology|November 25, 2003
Induction of an antitumour adaptive immune response elicited by tumour cells expressing de novo B7-1 mainly depends on the anatomical site of their delivery: the dose applied regulates the expansion of the responseSilvia Sartoris, Maria G Testi, Elisabetta Stefani, et al.
The Journal of Allergy and Clinical Immunology. in Practice|July 28, 2023
Mepolizumab in Patients With Severe Asthma and Comorbidities: 1-Year REALITI-A AnalysisMark C Liu, Diego Bagnasco, Andrea Matucci, et al.
Journal of Clinical Immunology|January 25, 2008
Prospective study on CVID patients with adverse reactions to intravenous or subcutaneous IgG administrationIsabella Quinti, Annarosa Soresina, Carlo Agostini, et al.
Pulmonary Pharmacology & Therapeutics|October 5, 2014
Asthma control in severe asthmatics under treatment with omalizumab: a cross-sectional observational study in ItalyFederica Novelli, Manuela Latorre, Letizia Vergura, et al.
Pageof 16

Showing results (91-100 of 156) with videos related to

Sort By:
Pageof 16
Biofilm|March 22, 2024
Pathogenic avian mycoplasmas show phenotypic differences in their biofilm forming ability compared to non-pathogenic species <i>in vitro</i>Salvatore Catania, Marco Bottinelli, Alice Fincato, et al.
Clinical Drug Investigation|September 8, 2018
Direct and Indirect Costs of Immunoglobulin Replacement Therapy in Patients with Common Variable Immunodeficiency (CVID) and X-Linked Agammaglobulinemia (XLA) in ItalyRaffaella Viti, Andrea Marcellusi, Alessandro Capone, et al.
Biomedicines|February 27, 2026
Immunogenicity in Fabry Disease: Current Issues, Coping Strategies, and Future DirectionsAndrea Matucci, Sandro Feriozzi, Elena Biagini, et al.
International Archives of Allergy and Immunology|December 28, 2006
Detection by flow cytometry of ESAT-6- and PPD-specific circulating CD4+ T lymphocytes as a diagnostic tool for tuberculosisLorenzo Cosmi, Laura Maggi, Veronica Santarlasci, et al.
European Journal of Immunology|September 26, 2018
Omalizumab dampens type 2 inflammation in a group of long-term treated asthma patients and detaches IgE from FcεRILaura Maggi, Beatrice Rossettini, Gianni Montaini, et al.
Clinical Drug Investigation|February 13, 2015
Subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency in routine clinical practice: the VISPO prospective multicenter studyAlessandra Vultaggio, Chiara Azzari, Cinzia Milito, et al.
Immunology|November 25, 2003
Induction of an antitumour adaptive immune response elicited by tumour cells expressing de novo B7-1 mainly depends on the anatomical site of their delivery: the dose applied regulates the expansion of the responseSilvia Sartoris, Maria G Testi, Elisabetta Stefani, et al.
The Journal of Allergy and Clinical Immunology. in Practice|July 28, 2023
Mepolizumab in Patients With Severe Asthma and Comorbidities: 1-Year REALITI-A AnalysisMark C Liu, Diego Bagnasco, Andrea Matucci, et al.
Journal of Clinical Immunology|January 25, 2008
Prospective study on CVID patients with adverse reactions to intravenous or subcutaneous IgG administrationIsabella Quinti, Annarosa Soresina, Carlo Agostini, et al.
Pulmonary Pharmacology & Therapeutics|October 5, 2014
Asthma control in severe asthmatics under treatment with omalizumab: a cross-sectional observational study in ItalyFederica Novelli, Manuela Latorre, Letizia Vergura, et al.
Pageof 16